鼻咽癌IMRT后放射性脑损伤转归影响因素分析

doi:10.3760/cma.j.issn.1004-4221.2018.05.002

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To explore the risk factors influencing the outcomes of radiation brain injury after intensity-modulated radiotherapy (IMRT) in patients diagnosed with nasopharyngeal carcinoma. Methods Clinical data of 1300 nasopharyngeal carcinoma patients treated with IMRT in our hospital during 2006 and 2013 were retrospectively analyzed. Fifty-eight patients presented with radiation brain injury after IMRT. MRI data of these patients during 3-24 months follow-up were collected. The clinical efficacy in the treatment of radiation brain injury was evaluated according to RECIST guidelines. Results Forty-six patients with intact follow-up data were enrolled. The median latency of radiation brain injury was 34 months. Patients were divided into the response (CR+PR) and non-response groups. The risk factors influencing the response rate during 10-12 months and 18-24 months were identified and analyzed. Univariate analysis demonstrated that gender, age, smoking history, T stage, and high-intensity treatment exerted no significant effect upon the Objective remission rate during these two time intervals periods. Patients treated with gangliosides obtained high response rate. The response rate was 68.8% in 10-12 months (P=0.000),and 81.8% in 18-24 months (P=0.008).Multivariate analysis revealed that use of gangliosides was a favorable factor for mitigating radiation brain injury in two time intervals (OR=19.8 and 13.5;P=0.001 and 0.005). Conclusions Use of gangliosides probably accelerates the healing of radiation brain injury, whereas the clinical efficacy remains to be elucidated by prospective clinical trials.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Hongzhi
	Wang Kai
	Qu Yuan
	Zhang Shiping
	Huang Xiaodong
	Yi Junlin
	Xiao Jianping
	Li Suyan
	Gao Li
	Xu Guozhen
	Luo Jingwei

Key words： Radiation induced brain injury Clinical outcome Ganglioside Nasopharyngeal neoplasm/intensity-modulated radiotherapy

Received: 11 November 2017

Corresponding Authors: :Luo Jingwei,Email:nqluo202@163.com

Cite this article:

Wang Hongzhi,Wang Kai,Qu Yuan et al. Analysis of risk factors of outcomes of radiation induced-brain injury after IMRT in nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(5): 441-444.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.05.002 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I5/441

[1]Su SF,Huang Y,Xiao WW,et al. Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma[J].Radiother Oncol,2012,104(3):312-316.DOI:10.1016/j.radonc.2012.06.012.
[2]Bakst RL,Lee N,Pfister DG,et al. Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma:a prospective trial[J].Int J Radiat Oncol Biol Phys,2011,80(1):148-153.DOI:10.1016/j.ijrobp.2010.01.026.
[3]Lee AWM,Foo W,Chappell R,et al. Effect of time,dose,and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,1998,40(1):35-42.DOI:10.1016/S0360-3016(97)00580-4.
[4]Wong,CS,Van der Kogel AJ.Mechanisms of radiation injury to the central nervous system:implications for neuroprotection[J].Mol Interv,2004,4(5):273-284.DOI:10.1124/mi.4.5.7.
[5]Belka C,Budach W,Kortmann RD,et al. Radiation induced CNS toxicity-molecular and cellular mechanisms[J].Br J Cancer,2001,85(9):1233-1239.DOI:10.1054/bjoc.2001.2100.
[6]Levin VA,Bidaut L,Hou P,et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system[J].Int J Radiat Oncol Biol Phys,2011,79(5):1487-1495.DOI:10.1016/j.ijrobp.2009.12.061.
[7]Wang XS,Ying HM,He XY,et al. Treatment of cerebral radiation necrosis with nerve growth factor:A prospective,randomized,controlled phase Ⅱ study[J].Radiother Oncol,2016,120(1):69-75.DOI:10.1016/j.radonc.2016.04.027.
[8]Tang YM,Rong XM,Hu WH,et al. Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy:a randomized controlled trial[J].J Neuro-Oncol,2014,120(2):441-447.DOI:10.1007/s11060-014-1573-4.
[9]Geisler FH,Dorsey FC,Coleman WP.Recovery of motor function after spinal-cord injury—a randomized,placebo-controlled trial with GM-1 ganglioside[J].N Engl J Med,1991,324(26):1829-1838.DOI:10.1056/NEJM199106273242601.
[10]Hadjiconstantinou M,Neff NH.GM1 ganglioside:in vivo and in vitro trophic actions on central neurotransmitter systems[J].J Neurochem,1998,70(4):1335-1345.DOI:10.1046/j.1471-4159.1998.70041335.x.
[11]Wang YX,King AD,Zhou H,et al. Evolution of radiation-induced brain injury:MR imaging-based study[J].Radiology,2010,254(1):210-218.DOI:10.1148/radiol.09090428.
[12]王孝深,胡超苏.放射性脑坏死的新认识与防治[J].中华放射肿瘤学杂志,2016,25(9):911-916.DOI:10.3760/cma.j.issn.1004-4221.2016.09.001.
Wang XS,Hu CS.Research advances in prevention and treatment of cerebral radiation necrosis[J].Chin J Radiat Oncol,2016,25(9):911-916.DOI:10.3760/cma.j.issn.1004-4221.2016.09.001.
[13]Torcuator R,Zuniga R,Mohan YS,et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis[J].J Neuro-Oncol,2009,94(1):63-68.DOI:10.1007/s11060-009-9801-z.
[14]Gonzalez J,Kumar AJ,Conrad CA,et al. Effect of bevacizumab on radiation necrosis of the brain[J].Int J Radiat Oncol Biol Phys,2007,67(2):323-326.DOI:10.1016/j.ijrobp.2006.10.010.
[15]董强.神经节苷脂GM1与神经系统疾病[J].国际脑血管病杂志,2009,17(12):881-888.DOI:10.3760/cma.j.issn.1673-4165.2009.12.001.
Dong Q.Ganglioside GM1 and central nervous system diseases[J].Int J Cerebrovasc Dis,2009,17(12):881-888.DOI:10.3760/cma.j.issn.1673-4165.2009.12.001.